File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Photodynamic therapy with verteporfin for subfoveal choroidal neovascularisation of pathologic myopia in Chinese eyes: A prospective series of 1 and 2 year follow up

TitlePhotodynamic therapy with verteporfin for subfoveal choroidal neovascularisation of pathologic myopia in Chinese eyes: A prospective series of 1 and 2 year follow up
Authors
Issue Date2004
PublisherBMJ Publishing Group. The Journal's web site is located at http://bjo.bmjjournals.com/
Citation
British Journal Of Ophthalmology, 2004, v. 88 n. 10, p. 1315-1319 How to Cite?
AbstractAims: To evaluate the visual and fluorescein angiographic outcomes of photodynamic therapy (PDT) with verteporfin in patients with subfoveal choroidal neovascularisation (CNV) caused by pathologic myopia in the Chinese. Methods: Prospective, non-comparative, two centre interventional study. Patients with CNV secondary to pathologic myopia of Chinese ethnicity were recruited and treated with a standard regimen of PDT with verteporfin. Results of this study in Chinese eyes with pigmented retinal pigment epithelium were compared with those from the Verteporfin in Photodynamic Therapy (VIP) Study of predominantly white eyes. Results: Thirty one and 22 eyes that completed the 12 month and 24 month follow up studies respectively were analysed. The mean and median best corrected visual acuities (BCVA) could be maintained at the baseline level at the 12 month and 24 month visits. Fourteen (63.6%) eyes had stable or improved BCVA at 24 months and six (27.3%) of them had a moderate gain in vision (improved by three or more lines). Visual results were comparable with that of the VIP study, but the average accumulative PDT treatments required in one and two years were 1.7 and 2.3 respectively, which were significantly less than 3.4 and 5.1 treatments in VIP study. Mean logMAR BCVA of the younger age group (<55 years) at 24 months was 0.41 (SD 0.29), which was significantly better than the older age group (≥ = 55 years) of 0.82 (SD 0.40) (Mann-Whitney U test, p = 0.029). Conclusions: PDT using the predetermined treatment protocol has achieved similar visual outcomes in the Chinese population as in white people with subfoveal myopic CNV over a 2 year study period. The complete cessation of CNV leakage can be accomplished, on average, with fewer PDT retreatments than reported in the VIP study. The disparity may be due to ethnic differences in these two populations.
Persistent Identifierhttp://hdl.handle.net/10722/123993
ISSN
2023 Impact Factor: 3.7
2023 SCImago Journal Rankings: 1.862
PubMed Central ID
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLam, DSCen_HK
dc.contributor.authorChan, WMen_HK
dc.contributor.authorLiu, DTLen_HK
dc.contributor.authorFan, DSPen_HK
dc.contributor.authorLai, WWen_HK
dc.contributor.authorChong, KKLen_HK
dc.date.accessioned2010-10-15T09:08:59Z-
dc.date.available2010-10-15T09:08:59Z-
dc.date.issued2004en_HK
dc.identifier.citationBritish Journal Of Ophthalmology, 2004, v. 88 n. 10, p. 1315-1319en_HK
dc.identifier.issn0007-1161en_HK
dc.identifier.urihttp://hdl.handle.net/10722/123993-
dc.description.abstractAims: To evaluate the visual and fluorescein angiographic outcomes of photodynamic therapy (PDT) with verteporfin in patients with subfoveal choroidal neovascularisation (CNV) caused by pathologic myopia in the Chinese. Methods: Prospective, non-comparative, two centre interventional study. Patients with CNV secondary to pathologic myopia of Chinese ethnicity were recruited and treated with a standard regimen of PDT with verteporfin. Results of this study in Chinese eyes with pigmented retinal pigment epithelium were compared with those from the Verteporfin in Photodynamic Therapy (VIP) Study of predominantly white eyes. Results: Thirty one and 22 eyes that completed the 12 month and 24 month follow up studies respectively were analysed. The mean and median best corrected visual acuities (BCVA) could be maintained at the baseline level at the 12 month and 24 month visits. Fourteen (63.6%) eyes had stable or improved BCVA at 24 months and six (27.3%) of them had a moderate gain in vision (improved by three or more lines). Visual results were comparable with that of the VIP study, but the average accumulative PDT treatments required in one and two years were 1.7 and 2.3 respectively, which were significantly less than 3.4 and 5.1 treatments in VIP study. Mean logMAR BCVA of the younger age group (<55 years) at 24 months was 0.41 (SD 0.29), which was significantly better than the older age group (≥ = 55 years) of 0.82 (SD 0.40) (Mann-Whitney U test, p = 0.029). Conclusions: PDT using the predetermined treatment protocol has achieved similar visual outcomes in the Chinese population as in white people with subfoveal myopic CNV over a 2 year study period. The complete cessation of CNV leakage can be accomplished, on average, with fewer PDT retreatments than reported in the VIP study. The disparity may be due to ethnic differences in these two populations.en_HK
dc.languageeng-
dc.publisherBMJ Publishing Group. The Journal's web site is located at http://bjo.bmjjournals.com/en_HK
dc.relation.ispartofBritish Journal of Ophthalmologyen_HK
dc.rightsBritish Journal of Ophthalmology. Copyright © B M J Publishing Group.-
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshChoroidal Neovascularization - drug therapy - ethnology - etiology-
dc.subject.meshMyopia - complications-
dc.subject.meshPhotochemotherapy - adverse effects - methods-
dc.titlePhotodynamic therapy with verteporfin for subfoveal choroidal neovascularisation of pathologic myopia in Chinese eyes: A prospective series of 1 and 2 year follow upen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0007-1161&volume=88&issue=10&spage=1315&epage=1319&date=2004&atitle=Photodynamic+therapy+with+verteporfin+for+subfoveal+choroidal+neovascularization+of+pathologic+myopia+in+Chinese+eyes:+a+prospective+series+of+1+and+2+years+follow-up.-
dc.identifier.emailLai, WW: wicolai@hku.hken_HK
dc.identifier.authorityLai, WW=rp00531en_HK
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1136/bjo.2004.041624en_HK
dc.identifier.pmid15377558-
dc.identifier.pmcidPMC1772358-
dc.identifier.scopuseid_2-s2.0-4744338913en_HK
dc.identifier.hkuros164016-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-4744338913&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume88en_HK
dc.identifier.issue10en_HK
dc.identifier.spage1315en_HK
dc.identifier.epage1319en_HK
dc.identifier.isiWOS:000223951100021-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridLam, DSC=35500200200en_HK
dc.identifier.scopusauthoridChan, WM=7403914485en_HK
dc.identifier.scopusauthoridLiu, DTL=8550730100en_HK
dc.identifier.scopusauthoridFan, DSP=7202965663en_HK
dc.identifier.scopusauthoridLai, WW=7402231098en_HK
dc.identifier.scopusauthoridChong, KKL=7102553915en_HK
dc.identifier.issnl0007-1161-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats